---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-025304"
form_type: "8-K"
ticker: "TGTX"
cik: "0001001316"
company_name: "TG THERAPEUTICS, INC."
filed_at: "2026-08-03T11:05:58+00:00"
generated_at: "2026-08-03T11:10:12.966969+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# TG Therapeutics Q2 2026 revenue $240M, raises FY2026 BRIUMVI guidance to ~$890-905M

## Summary
- Q2 2026 total global revenue ~$240M; BRIUMVI U.S. net product revenue $227.7M, up 64% YoY.
- Raises FY2026 BRIUMVI U.S. net product revenue target to ~$890-905M; total global revenue target ~$950M.
- Net income $7.8M in Q2 2026 vs $28.2M in Q2 2025; R&D expense increased to $95.3M due to subcutaneous manufacturing.
- Positive Phase 3 ENHANCE trial met primary endpoint; single 600mg infusion regimen eliminates Day 15 infusion.
- Cash position $612.3M as of June 30, 2026; operating expense target $350-400M (excl. non-cash comp) plus ~$100M for subcutaneous mfg.

## SEC filing metadata
- accession: 0001437749-26-025304
- form_type: 8-K
- ticker: TGTX
- cik: 0001001316
- company_name: TG THERAPEUTICS, INC.
- filed_at: 2026-08-03T11:05:58+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001316/000143774926025304/0001437749-26-025304-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001316/000143774926025304/tgtx20260730_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-025304
- JSON: https://secwatch.observer/filing/0001437749-26-025304.json
- Plain text: https://secwatch.observer/filing/0001437749-26-025304.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.